Investors

Read Our Most Recent Shareholder Letter

READ NOW

Company Overview

Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). AXIM’s NeuCovix™ is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis.

Investor Presentation

DOWNLOAD

Email Alerts

Stay informed and receive company updates straight to your inbox

Recent News

AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files Amended Emergency Use Authorization with FDA for its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations

by | Aug 30, 2021 |

SAN DIEGO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease diagnostics, announced today that the...

Latest Annual Filing

Fiscal Year Ended Dec 31, 2019

View Filing

Investor Contact Information

Company

AXIM Biotechnologies, Inc.
6191 Cornerstone Court, E., Suite 114,    San Diego, CA 92121
T: +1 858 923-4422

Investor Relations

T: 888-759-0844
investors@aximbiotech.com

Transfer Agent

Action Stock Transfer Corporation
2469 E. Fort Union Blvd
Suite 214
Salt Lake City, UT 84121
T: 801-274-1088
info@actionstocktransfer.com
www.actionstocktransfer.com